Current Therapeutic Limitation

“Less than 5% of Chemotherapy is delivered to its Target Tumor Site”

Chemotherapeutic agents are the most commonly administered drugs to treat cancer, the second leading cause of death in the United States.  Despite therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapy.  Researchers have reported that just 0.5% to 3.5% of systemically delivered chemotherapy is delivered to its target tumor site.

Sigyn Solution

To overcome these limitations, we designed a therapeutic system comprised of ChemoPrepTM to enhance tumor site delivery of chemotherapy and ChemoPureTM to reduce its toxicity. 

To enhance the delivery of chemotherapeutic agents, we designed ChemoPrepTM to deplete the circulating presence of tumor-derived extracellular vesicles or exosomes (Tumor-EXs) that promote cancer progression and diminish treatment efficacy. As compared to non-cancer subjects, exosome populations are immensely concentrated (10x to >500x higher) in the bloodstream of those suffering from cancer.

Tumor-EXs are known to decoy and directly inhibit chemotherapeutic agents from reaching their tumor cell targets. Recent studies also reveal that Tumor-EXs can export delivered chemotherapeutic agents back out of cancer cells.  The ability of Tumor-EXs to sequester chemotherapeutic agents is considered a key mechanism that contributes to multidrug resistance, a critical factor associated with treatment failure and short-term survival.

Based on the increasing prevalence of cancer, analysts at Data Bridge Market Research project the global market for chemotherapeutic drugs will increase from $42.9 billion in 2021 to $89.3 billion in 2029.  ChemoPrepTM establishes a candidate strategy to optimize the delivery of these chemotherapy agents.

If demonstrated to be clinically effective, ChemoPrepTM would overcome a therapeutic limitation in healthcare and likely provide a competitive advantage to organizations focused on the commercialization of cancer chemotherapies. 

ChemoPrepTM is associated with a provisional patent submission entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” that has been filed with the United States Patent and Trademark Office (“USPTO”).